title: Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.
abstract: BACKGROUND
  Dipeptide peptidase-4 (DPP-4) inhibitors such as saxagliptin are established and efficacious oral therapies in the management of type 2 diabetes. These agents have the potential to confer significant benefits in glycemic control without the risk of weight gain and hypoglycemia, which may be associated with other medications used to treat type 2 diabetes.
  
  
  METHODS
  This review examines the pharmacokinetics, efficacy and tolerability of saxagliptin for the management of type 2 diabetes.
  
  
  CONCLUSIONS
  Saxagliptin is routinely used in the management of type 2 diabetes as monotherapy, and in combination with other oral agents and insulin. Robust clinical trials have shown consistent improvements in glycated hemoglobin, fasting and postprandial glucose levels, with few adverse effects. The agent is well tolerated with low rates of hypoglycemia in the absence of insulin or sulphonylurea therapy.
authors.affiliation: a Department of Diabetes & Endocrinology , Morriston Hospital, ABM University Health Board , Swansea , UK.
authors.forename: Rose
authors.initials: R
authors.lastname: Anderson
authors.affiliation: a Department of Diabetes & Endocrinology , Morriston Hospital, ABM University Health Board , Swansea , UK.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Hayes
authors.affiliation: a Department of Diabetes & Endocrinology , Morriston Hospital, ABM University Health Board , Swansea , UK.|b Diabetes Research Group , Institute of Life Sciences, Swansea University , Swansea , UK.
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Stephens
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000493:pharmacokinetics / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D019518:Postprandial Period; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000218:Adamantane; D001786:Blood Glucose; D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007328:Insulin; D013453:Sulfonylurea Compounds; C502994:saxagliptin
keywords: DPP-4; glucagon-like peptide 1; saxagliptin